BAUSCH HEALTH COMPANIES WKN: A2JQ1X ISIN: CA0717341071 Kürzel: BHC Forum: Aktien Thema: Hauptdiskussion

https://seekingalpha.com/news/3972676-bausch-health-soars-after-court-ruling-in-patent-dispute-with-norwich-pharma?

🚀

https://stocktwits.com/symbol/BHC

Ich rechne heute mit 20% plus

https://www.marketbeat.com/stocks/NYSE/BHC/earnings/

https://www.reuters.com/business/bausch-lomb-name-brent-saunders-ceo-wsj-2023-02-15/

Bausch Health (NYSE:BHC) is up 11% after the US FDA issued updated guidance for the company's irritable bowel syndrome with diarrhea drug Xifaxan (rifaximin) that will require generic drugmakers to conduct pharmacokinetic and in vitro bioequivalence studies. According to the guidance, generic drugmakers have two options. They can either conduct four pharmacokinetic bioequivalence studies and in vitro bioequivalence studies (comparative dissolution); or four pharmacokinetic bioequivalence studies, in vitro bioequivalence studies (comparative dissolution), and two clinical endpoint bioequivalence studies. The agency also noted that waiver requests for in vitro testing is "not applicable." The guidance is seen as a blow to companies with rifaximin abbreviated New Drug Applications (ANDAs) seeking to get their products onto the market. In September, the FDA granted tentative approval to Norwich Pharmaceuticals' rifaximin ANDA. In July, a federal judge issued an order in favor of Norwich in a patent dispute on Xifaxan with Bausch Health (BHC).

FDA Update

Gerüchteküche...es geht steil hoch

Wow steigt gut heute

Bausch expects Xifaxan patent to hinder generic entry in US until 2029 despite approval https://seekingalpha.com/news/3881587-bausch-expects-xifaxan-generic-to-not-enter-market-until-2029-despite-approval-due-to-patent-protection?source=WhatsApp

https://www.thestreet.com/quote/BHC

Und ungewöhnlich, daß der Handel so lange ausgesetzt wurde Ein Schelm, wer... Ich habe noch eine kleine Portion zu 4,50 nachgeordert, mal sehen, was das gibt.

Nachbörslich 24% gestiegen....was ein fieses Spiel. Als ob hier Mal eben 1,5Mrd verbrannt wären.

Trading in Bausch Health Companies (BHC) was briefly halted Thursday morning and is currently down 50% after a Delaware federal court judge issued an oral order on patent litigation over Xifaxan. Judge Richard Andrews has directed Bausch (BHC) subsidiary Salix Pharmaceuticals to meet with generics manufacturer Norwich Pharmaceuticals to meet and file a joint final judgment by Aug. 3. Norwich is trying to market a generic version of Xifaxan (rifaximin), an irritable bowel syndrome with diarrhea drug. "The parties should proceed on the assumption that the Court's conclusions will be: Norwich's ANDA will induce infringement of the asserted HE patent claims, and would induce infringement of the asserted IBS-D, and Polymorph patent claims if they were valid.,"